Oramed Pharmaceuticals Inc. completed the sale of its wholly-owned subsidiary, Oratech Pharma, Inc., to Lifeward Ltd. on March 25, 2026. In consideration for Oratech, Oramed received 1,250,363 Lifeward Ordinary Shares, 1,006,113 Pre-Funded Warrants (exercise price $0.0001/share), and Share Purchase Warrants for up to 1,296,296 Lifeward Ordinary Shares (initial exercise price $5.40/share). Oramed will also receive ongoing revenue-based payments equal to 4% of Net Revenue from Lifeward's ReWalk Personal Exoskeleton products and related extended warranties for up to 10 years, or until a maximum amount is reached, or Lifeward's market capitalization exceeds $200 million. Concurrently, Oramed invested $9,000,000 in Lifeward by purchasing senior secured convertible notes in a private placement. These notes are convertible into Lifeward Ordinary Shares at an initial conversion price of $5.40 per share. Oramed also received Purchase Agreement Warrants to acquire up to 1,666,666 Lifeward Ordinary Shares at an initial exercise price of $5.40 per share as part of the notes purchase.